Completed NA INTERVENTIONAL 1-arm NCT01828762

Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy (DC-TC)

Clinical Study of the Safety of Autologous Immune Cell Therapy in Primary Hepatocellular Carcinoma Patients Following Resection and TACE Therapy

Sponsor: China Cell Technology Ltd.

Conditions Primary Hepatocellular Carcinoma

Interventions DC-TC+GM-CSF

Updated 6 times since 2017 Last updated: Dec 20, 2013 Started: Dec 31, 2012 Primary completion: Dec 31, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Primary Hepatocellular Carcinoma, this trial is completed. The trial is conducted by China Cell Technology Ltd. and has accumulated 6 data snapshots since 2012. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Mar 2020 — Jan 2021 [monthly]

Completed NA
Jun 2018 — Mar 2020 [monthly]

Completed NA

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed NA

First recorded

Dec 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

China Cell Technology Ltd.
No.85 Hospital, Changning, Shanghai, China
Shanghai AbelZeta Ltd.

Data source: Shanghai AbelZeta Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China